Retatrutide
GLP-1 / GIP / glucagon triple agonist. Retatrutide is investigational and not approved for any use.
Key facts
- Class
- GLP-1 / GIP / glucagon triple agonist
- Also called
- reta, GLP-3
- Vial sizes sold
- 5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 24 mg, 30 mg, 36 mg, 40 mg, 50 mg, 60 mg
- Community-reported sizes
- Half-life
- approximately 6 days
- subcutaneous, in people · Lancet 2022, PMID 36354040
- FDA status
- Not approved
- Investigational · phase 3
- WADA
- Prohibited (S0)
- In and out of competition
Retatrutide guides
Explained
Questions
Evidence at a glance
Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.
| Condition | Human studies | Animal studies | Studies we summarised | Evidence grade |
|---|---|---|---|---|
| Weight loss | 71 | 7 | 13 | Human RCT evidence, 4 of 4The New England journal of medicine 2026, PMID 42814954 |
| Diabetes | 53 | 6 | 5 | Human RCT evidence, 4 of 4Lancet 2026, PMID 42810372 |
| Heart health | 23 | 0 | 3 | Human RCT evidence, 4 of 4Diabetes, obesity & metabolism 2026, PMID 42608321 |
| Joint pain | Not in our ledger | Not in our ledger | 1 | Human RCT evidence, 4 of 4The New England journal of medicine 2026, PMID 42814954 |
| Liver | 18 | 4 | 2 | Human RCT evidence, 4 of 4Nature medicine 2024, PMID 38858523 |
| Metabolism | 6 | 4 | 4 | Human RCT evidence, 4 of 4Lancet 2026, PMID 42250575 |
| Gut health | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.
What sets retatrutide apart
Its distinguishing feature is a third target: it activates GIP, GLP-1 and glucagon receptors together.[15]
The only half-life value found is from a phase 1b trial in people with type 2 diabetes: about 6 days.[16]
Strongest finding
In the phase 3 obesity trial, mean weight change at the highest dose was -25.0%, against -3.9% on placebo.[2]
In people with obesity and type 2 diabetes, gastrointestinal events were more common on retatrutide. Diarrhoea occurred in 27%, 34% and 34% across the 4, 9 and 12 mg groups against 13% on placebo.[12]
Biggest open question
Tolerability is the open question: a network meta-analysis of weight-loss drugs reported the highest adverse-event risk for retatrutide.[22]
In the type 2 diabetes monotherapy trial, adverse-event discontinuations were 2-5% on retatrutide against 0% on placebo.[15]
Regulatory path
Drugs@FDA has no entry for retatrutide, which is still an investigational drug.[6]
WADA does not name retatrutide; it falls under the catch-all for unapproved substances in S0.[5]
Compared with
Common stacks
Retatrutide is often sold pre-mixed or combined with other peptides. No controlled study has tested these combinations; the pages below cover the math and what each part has been studied for.
Common questions
Is Retatrutide FDA approved?
No. Retatrutide is investigational (investigational · phase 3) and not approved for any use.
Is Retatrutide banned in sport?
Yes. Prohibited by WADA (S0), so it is prohibited at all times for tested athletes.
How much water goes in a 10 mg vial?
That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.
What is retatrutide?
An investigational drug that activates three receptors: GIP, GLP-1 and glucagon.[15]
What does retatrutide do?
In a phase 3 obesity trial it cut mean body weight by up to 25.0% versus 3.9% with placebo.[2]
What is the retatrutide half-life?
About 6 days, from a phase 1b trial in type 2 diabetes.[16]
Is retatrutide approved?
No. The Drugs@FDA search for it returned no matches.[6]
What is LY3437943, and what does GLP-3 mean?
LY3437943 is the development code used in the trial records. GLP-3 is a seller nickname quoted in an FDA warning letter; Drugs@FDA lists no approved brand name.[23]
Sources
- 1Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (Jastreboff AM et al.)New England Journal of Medicine · 2023PMID 37366315Accessed 2 Oct 2026
- 2Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1; Jastreboff AM et al.)New England Journal of Medicine · 2026PMID 42814954Accessed 2 Oct 2026
- 3A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities (NCT04881760; arms and posted results)ClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
- 4Warning letter to NuScience Peptides LLC (ref. 733652), 24 Aug 2026, one of five letters to research-peptide sellers issued that dayU.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 5World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 6United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "retatrutide" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 7World Anti-Doping Code: Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 8Retatrutide phase 3 TRIUMPH-1 results publishedNEJM (PubMed 42814954) · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 10Eli Lilly sues six retatrutide sellersEli Lilly (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
- 11Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 12Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2026PMID 42810372Accessed 2 Oct 2026
- 13Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
- 14Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.Nature medicine · 2024PMID 38858523Accessed 2 Oct 2026
- 15Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 42250575Accessed 2 Oct 2026
- 16LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
- 17PubMed search: retatrutide[tiab] OR LY3437943[tiab] (197 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 18PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab]) (96 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 19PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND (obesity[tiab] OR diabetes[tiab] OR liver[tiab] OR osteoarthritis[tiab]) AND "Clinical Trial"[pt] (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 20PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (9 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 21PubMed search: (SYNCHRONIZE[tiab] OR TRIUMPH[tiab] OR GLORY[tiab] OR DREAMS[tiab]) AND (survodutide[tiab] OR retatrutide[tiab] OR mazdutide[tiab]) (27 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 22Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.Obesity (Silver Spring, Md.) · 2025PMID 40685589Accessed 2 Oct 2026
- 23Official web pageOfficial web page · web page
Found an error? Report a correction.